Glu mutation in human microglia results in late-onset neurodegeneration in individuals with histiocytosis (excess of macrophages) (3) . This suggests that microglial dysfunction can be the primary cause of neurological diseases in humans.
Microglia can also promote neurodegeneration secondary to infections (e.g., HIV infection), exposure to misfolded proteins (as occurs in many neurodegenerative disorders), or CNS injury. Whereas microglia were traditionally considered to quickly respond to any pathological event in the brain and to help restore homeostasis (albeit at the price of potential bystander damage, such as through the release of toxic molecules or proinflammatory mediators), it is now becoming clear that this passive role of microglia in responding to damage falls short in reflecting their complex functions in the CNS. Indeed, microglia may themselves initiate neural dysfunction and neurodegeneration through loss of homeostatic and/or gain of aberrant function (see the figure) . Consistently, many genetic alterations that are associated with increased risk for neurological and psychiatric disorders, including schizophrenia, autism spectrum disorder, frontotemporal dementia, and Alzheimer's disease (AD), affect genes that are highly expressed by microglia. As a result, microglial functions have emerged as possible targets for CNS disorders.
Given their embryonic origin and dependence on self-maintenance in the absence of turnover with circulating monocytes, microglia may be much more vulnerable to aging and degeneration than previously assumed. Recent transcriptomic studies have revealed substantial age-dependent changes in the expression of genes involved in cell motility, adhesion, axonal guidance, and immune function in microglia, reminiscent of the changes observed in some neurodegenerative diseases (4) . The sialic acid-binding receptor CD22 is up-regulated on aged microglia, and CD22 blockade restores microglial homeostasis and improves cognitive function in aged mice (5) , underscoring the therapeutic potential of targeting microglial functions. A disease-associated microglia state was recently identified in the brains of AD transgenic mice that may exert protective functions by clearing amyloid-b protein aggregates, which are thought to be pathological in AD (6) . These neurodegeneration-associated microglia express many of the genes that have been associated with increased risk for AD and other neurodegenerative disorders in genome-wide association studies, including cathepsin D (CTSD), lipoprotein lipase precursor (LPL), TYRO protein tyrosine kinase-binding protein (TYROBP), apolipoprotein E (APOE), and triggering receptor expressed on the myeloid cells 2 (TREM2). Single-cell transcriptomic analysis of the prefrontal cortex in humans with AD pathology confirmed the presence of disease-associated microglia signatures (7) . Among the most highly expressed genes in microglia were secreted phosphoprotein 1 (SPP1), protein tyrosine phosphatase receptor type G (PTPRG), apolipoprotein C1 (APOC1), and APOE, all of which have been associated with increased risk of AD.
Disease-associated microglia states were also discovered in the brains of humans with multiple sclerosis (MS), including SPP1 + microglia and CTSD + microglia (8) . Their transcriptional profiles resembled those of microglia phenotypes identified in a mouse model of demyelination, which is a hallmark of MS pathology (8) . In contrast to neurodegeneration-associated microglia, increased expression of genes involved in interactions with other immune cells, including CD74, and the major histocompatibility complex (MHC) class II molecules, was detected in MS-associated microglia. This may reflect the chronic neuroinflammation that is observed in MS.
Technological advances in single-cell mass cytometry have enabled the validation of some of the transcriptional signatures of disease-associated microglia at the protein level (single-cell proteomics) (9) . These studies detected differences in the immunophenotypic signatures of microglia between mouse models of neurodegeneration and neuroinflammation; whereas the former showed up-regulation of CD14 in a small subset of microglia, the latter were characterized by the global up-regulation of MHC class II and stem cell antigen 1 (SCA1) in microglia. Future lineage-tracing studies will help to determine whether disease-associated microglia are a distinct, albeit heterogenous population, a mixture of different subpopulations, or a reflection of dynamic states of microglia.
From a therapeutic perspective, it would seem attractive to specifically target these disease-associated microglia phenotypes based on the molecular signatures according to the type of neuropathology. The modulation of checkpoint mechanisms that normally keep microglia in a homeostatic state and are down-regulated during the development of disease-associated microglia, such as the receptors CX3C chemokine receptor 1 (CX3CR1), P2Y purinoceptor 12 (P2Y12). and TGF-b1 receptor (TGFBR1), as well as the TREM2-APOE pathway, appears particularly promising (6) . By contrast, long-term depletion of microglia or administration of immunosuppressant drugs may not be the preferred treatment choice for neuropsychiatric disorders due to the resulting loss of homeostatic functions of microglia, such as the modulation of synaptic plasticity, the supply of trophic factors for neurons and other SCIENCE sciencemag.org GRAPHIC: KELLIE HOLOSKI/SCIENCE types of glia, and the participation in pathogen defense.
Microglia are highly dependent on environmental signals to maintain their homeostatic phenotype. This results in distinct brain region-dependent transcriptional identities, which are associated with differential vulnerability to aging (4) . Immune profiling of human brain microglia by single-cell proteomics recently revealed a core immunophenotypic signature with considerable regional heterogeneity (10) . Notably, microglia subsets in the frontal and temporal cortex expressed higher amounts of mannose receptor C type 1 (CD206) compared to microglia subsets in the subventricular zone and thalamus that expressed higher levels of the proliferation markers cyclin A, cyclin B1, and Ki67. These findings have important therapeutic implications because microglia may be targeted not only in a disease-specific, but also in a brain region-specific, manner. This refined approach could facilitate the treatment of CNS disorders with regionally confined pathology, such as stroke or Parkinson's disease, by enabling site-specific modulation of microglial function that spares nonaffected tissue.
Unfortunately, microglia cannot be easily accessed in the CNS. The blood-brain barrier, which is formed by tight junctions between endothelial cells in cerebral blood vessels, regulates the trafficking of cells and larger molecules into the CNS. As an exception to the rule, the choroid plexuses and circumventricular organs contain fenestrated blood vessels that facilitate exchange processes with the periphery. The therapeutic relevance of these gates into the CNS from peripheral blood has yet to be fully explored. Initial attempts to target genetically engineered hematopoietic cells injected into the blood to sites of damage in the brain in order to replace microglia relied on CNS irradiation (11). In two landmark clinical studies on inherited peroxisomal and lysosomal storage disorders (X-linked adrenoleukodystrophy and metachromatic leukodystrophy) that result in severe motor and cognitive deficits, children were treated successfully with chemotherapy, which also conditions the CNS for immune cell engraftment. This was followed by reinfusion of hematopoietic stem cells that were genetically corrected ex vivo with lentiviral vectors, resulting in expression of the deficient proteins in the CNS (12, 13) .
Dysfunctional microglia can also be depleted locally or throughout the brain with pharmacological inhibitors of CSF1R signaling or with liposome-encapsulated bisphosphonates that trigger apoptosis specifically of microglia. As the microglial population is under strong homeostatic pressures, rapid replenishment occurs from local pools (14) . The newly engrafted cells temporarily acquire functions that are distinct from those of preexisting dysfunctional microglia (14) . The process of replenishment also provides an opportunity to introduce gene-modified cells. Competition of myeloid cells (such as monocytes and macrophages) for niches within the CNS that have been generated by the loss or dysfunction of microglia can affect the efficiency of replacement with engineered cells. The factors that govern competitive engraftment are not fully understood and have yet to be exploited therapeutically. Aged microglia or microglia carrying genetic and/or epigenetic defects may have a competitive disadvantage. Thus, future attempts to modify the function of microglia or microglia subpopulations, e.g., by gene editing, on a whole-brain or region-specific level need to consider microglia population dynamics. Along these lines, it is important to note that somatic mosaicism (cell clones with distinct acquired mutations) in microglia plays a role in CNS disorders, such as histiocytosis and ALSP (3, 15) . The selection of the (regionally) "fittest" microglia may be exploited for therapeutic purposes, e.g., gene-edited microglia may outcompete microglia with disease-causing mutations, and microglia may be engineered that maintain homeostatic functions or resist toxic microenvironments.
Many obstacles need to be overcome before microglia can be exploited for the therapy of CNS disorders. It is likely to be important to develop drugs that specifically target disease-associated microglia states without affecting homeostatic microglia or peripheral tissue macrophage populations. These compounds would need to cross the blood-brain barrier to gain access to the brain parenchyma, and in the case of gene engineering, efficient vectors for human microglia need to be available that do not trigger inflammation. The protocols for the engraftment of genetically engineered myeloid cells in the human CNS also need to be optimized. Interventions may need to be temporally restricted if disease-associated microglia are dynamic states. Thus, the development of new radioligands for positron emission tomography (PET)-based monitoring of microglial activity in the human brain, e.g., isotope-labeled ligands for P2Y12 or TREM2 receptors, will be of importance. Dynamic modulation of microglial function (activation and inhibition) to account for the spatiotemporally differential roles of diseaseassociated microglial states, and for the complex interactions of microglia with other immune cells, such as borderassociated brain macrophages, astrocytes, oligodendrocytes, and peripheral immune cells, as well as endothelial cells, will be required over the disease course, which is a daunting task. Nevertheless, our understanding of the cross-talk between microglia and other cell types in the CNS and periphery has substantially increased in recent years and may eventually allow us to modulate microglial function indirectly and without ingress into the CNS. Given the lack of effective therapeutic options for many neurological and psychiatric diseases, further understanding and eventual targeting of microglial functions in the CNS could hold promise. j
